ALLOGENE THERAPEUTICS, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-1
Book Value Per Share
$1
Free Cash Flow Per Share
$-1
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-1
Return on Equity
-53.4%
Return on Assets
-39.6%
Return on Invested Capital
-46.3%
Current Ratio
7.93
Quick Ratio
7.93
Asset Turnover
0.00
R&D / Revenue
874086.4%
SBC / Revenue
235195.5%
Capex / Revenue
3154.5%
Working Capital
$225M
Net Current Asset Value
$134M
Invested Capital
$293M
OCF / Net Income
0.78
FCF / Net Income
0.78
Accruals Ratio (Sloan)
-10.0%
Net Debt
$-52M
Net Debt / EBITDA
0.26
Interest Coverage
-194.71
Cash Coverage
-138.83
Capex Coverage
-386.65
Tangible Common Equity
$293M
TCE / Total Assets
70.3%
NOPAT
$-165M
Cash ROIC
-41.9%
WC / Revenue
1217559.1%
Capex / D&A
0.03
Reinvestment Rate
5.7%
Asset Growth vs Revenue Growth
75.8%
Revenue 5Y CAGR
-81.9%
Book Value 5Y CAGR
-17.0%
Stock Price (FY-end)
$1
Market Cap
$302M
P/S Ratio
18861.32
P/B Ratio
1.03
P/TB Ratio
1.03
Enterprise Value
$251M
EV / Sales
15442.32
FCF Yield
-49.5%
Shareholder Yield
-12.5%
R&D Yield
49.7%
Capex Yield
0.1%
Shares Variation (YoY)
13.2%
Beta (5Y)
1.53
Cost of Equity
12.2%
52W High
$3
52W Low
$1
Trailing Return 1Y
-37.4%
Trailing Return 5Y
-95.1%
F-Score (Piotroski)
2.00
Z-Score (Altman)
-6.31
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.